Analyst: Buy AstraZeneca On The Turnaround Story

By: via Benzinga
Following AstraZeneca plc (ADR) (NYSE: AZN)’s strong start to 2017, including a positive data report for breast cancer treatment ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.